Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Tsuyoshi Shirakawa; Akitaka Makiyama; Mototsugu Shimokawa; Taiga Otsuka; Yudai Shinohara; Futa Koga; Yujiro Ueda; Junichi Nakazawa; Satoshi Otsu; Azusa Komori; Shiho Arima; Masaru Fukahori; Hiroki Taguchi; Takuya Honda; Taro Shibuki; Kenta Nio; Yasushi Ide; Norio Ureshino; Toshihiko Mizuta; Kenji Mitsugi; Koichi Akashi; Eishi Baba

doi:10.1038/s41598-024-55673-7

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

Sci Rep. 2024 Mar 4;14(1):5311. doi: 10.1038/s41598-024-55673-7.

Authors

Tsuyoshi Shirakawa^{1

2}, Akitaka Makiyama^{3

4}, Mototsugu Shimokawa^{5

6}, Taiga Otsuka^{7

8}, Yudai Shinohara³, Futa Koga⁹, Yujiro Ueda¹⁰, Junichi Nakazawa¹¹, Satoshi Otsu¹², Azusa Komori^{12

13}, Shiho Arima¹⁴, Masaru Fukahori^{15

16}, Hiroki Taguchi^{17

18}, Takuya Honda¹⁹, Taro Shibuki^{20

21}, Kenta Nio^{22

23}, Yasushi Ide^{24

25}, Norio Ureshino^{7

26}, Toshihiko Mizuta^{20

27}, Kenji Mitsugi^{28

29}, Koichi Akashi³⁰, Eishi Baba³¹

Affiliations

¹ Department of Medical Oncology, Fukuoka Wajiro Hospital, 2-2-75 Wajirogaoka, Higashi-Ku, Fukuoka-Shi, Fukuoka, 811-0213, Japan.
² Department of Internal Medicine, Karatsu Higashi-Matsuura Medical Association Center, 2566-11 Chiyoda-machi, Karatsu-Shi, Saga, 847-0041, Japan.
³ Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-Ku, Kitakyushu-Shi, Fukuoka, 806-8501, Japan.
⁴ Cancer Center, Gifu University Hospital, 1-1 Yanagido, Gifu-Shi, Gifu, 501-1194, Japan.
⁵ Clinical Research Institute, National Kyushu Cancer Center, 3-1-1 Notame, Minami-Ku, Fukuoka-Shi, Fukuoka, 811-1395, Japan.
⁶ Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube-Shi, Yamaguchi, 755-8505, Japan.
⁷ Department of Medical Oncology, Saga-Ken Medical Center Koseikan, 400 Kase-Machi, Saga-Shi, Saga, 840-8571, Japan.
⁸ Department of Internal Medicine, Minato Medical Clinic, 3-11-3 Nagahama, Chuo-Ku, Fukuoka-Shi, Fukuoka, 810-0072, Japan.
⁹ Department of Hepatobiliary and Pancreatology, Saga-Ken Medical Center Koseikan, 400 Kase-Machi, Saga-Shi, Saga, 840-8571, Japan.
¹⁰ Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, 2-1-1 Nagamine-Minami, Higashi-Ku, Kumamoto-Shi, Kumamoto, 861-8520, Japan.
¹¹ Department of Medical Oncology, Kagoshima City Hospital, 37-1 Uearata-Cho, Kagoshima-Shi, Kagoshima, 890-8760, Japan.
¹² Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-Machi, Yufu-Shi, Oita, 879-5593, Japan.
¹³ Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama-Shi, Ehime, 791-0280, Japan.
¹⁴ Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima-Shi, Kagoshima, 890-8520, Japan.
¹⁵ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-Shi, Fukuoka, 830-0011, Japan.
¹⁶ Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan.
¹⁷ Department of Gastroenterology, Saiseikai Sendai Hospital, 2-46 Harada-Cho, Satsumasendai-Shi, Kagoshima, 895-0074, Japan.
¹⁸ Department of Gastroenterology, Kagoshima City Hospital, 37-1 Uearata-Cho, Kagoshima-Shi, Kagoshima, 890-8760, Japan.
¹⁹ Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki-Shi, Nagasaki, 852-8501, Japan.
²⁰ Department of Internal Medicine, Imari Arita Kyoritsu Hospital, 860 Ninose-Ko, Arita-Cho, Nishi-Matsuura-Gun, Saga, 849-4193, Japan.
²¹ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanohara, Kashiwa-Shi, Chiba, 277-8577, Japan.
²² Department of Medical Oncology, Sasebo Kyosai Hospital, 10-17 Shimanji-Cho, Sasebo-Shi, Nagasaki, 857-8575, Japan.
²³ Department of Medical Oncology, Hamanomachi Hospital, 3-3-1 Nagahama, Chuo-Ku, Fukuoka-Shi, Fukuoka, 810-8539, Japan.
²⁴ Department of Internal Medicine, Karatsu Red Cross Hospital, 2430 Watada, Karatsu-Shi, Saga, 847-8588, Japan.
²⁵ Department of Internal Medicine, National Hospital Organization Saga Hospital, 1-20-1 Hinode, Saga-Shi, Saga, 849-8577, Japan.
²⁶ Department of Medical Oncology, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu-Shi, Chiba, 292-8535, Japan.
²⁷ Department of Internal Medicine, Fujikawa Hospital, 1-2-6 Matsubara, Saga-Shi, Saga, 840-0831, Japan.
²⁸ Department of Medical Oncology, Sasebo Kyosai Hospital, 10-17 Shimanji-Cho, Sasebo-Shi, Nagasaki, 857-8575, Japan. kenji.mitsugi@sb.kkr.or.jp.
²⁹ Department of Medical Oncology, Hamanomachi Hospital, 3-3-1 Nagahama, Chuo-Ku, Fukuoka-Shi, Fukuoka, 810-8539, Japan. kenji.mitsugi@sb.kkr.or.jp.
³⁰ Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi‑ku, Fukuoka, 812-8582, Japan.
³¹ Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi‑ku, Fukuoka, 812-8582, Japan.

No abstract available

Publication types

Published Erratum